MedTrace Logo

Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study

NCT02489760 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-01-20

No results posted yet for this study

Summary

To determine the safety and efficacy of switch effects to adalimumab in etanercept-treated AS patients.

Conditions

Interventions

BIOLOGICAL

Adalimumab

The treatment arm will receive adalimumab 40 mg subcutaneously biweekly

BIOLOGICAL

Etanercept

The control arm will continue etanercept 25 mg subcutaneously twice a week

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Wei C- C, M.D. · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2015-12-31
Completion
2016-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02489760 on ClinicalTrials.gov